<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Diaz et al., in vivo and in vitro, observe a reduced B cell-intrinsic inflammation and an improved antibody response with a consequent increase in the response to the influenza vaccine in type 2 diabetes patients taking MET. In conclusion, their results show that MET improves B cell responses through reduction in B cell-intrinsic inflammation and increased AMPK function, so AMPK may be a therapeutic target [
 <xref ref-type="bibr" rid="CR39">39</xref>].
</p>
